This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
cannabis: Archive
Can Cannabis Strength in Canada Drive Canopy's Q3 Earnings?
by Zacks Equity Research
CGC heads into Q3 with Canada cannabis momentum, new product launches and a $50.6M revenue view ahead of Feb. 6 results.
CAHPositive Net Change MMSIPositive Net Change VCYTNegative Net Change CGCPositive Net Change
cannabis earnings
TLRY vs. CGC: Which Cannabis Stock is the Better Investment Now?
by Moumi Mondal
Tilray Brands' international revenue surge, beverage scale and strong cash position give it an edge over Canopy Growth as cannabis regulation and demand continue to evolve.
CGCPositive Net Change TLRYNegative Net Change
cannabis medical
Company News for Oct 10, 2025
by Zacks Equity Research
Companies in The News Are: TLRY,DAL,PEP,AZZ
DALPositive Net Change PEPPositive Net Change AZZNegative Net Change TLRYNegative Net Change
airlines cannabis consumer-staples industrial-products
Q3 Earnings Season Begins On Positive Note
by Zacks Equity Research
Q3 Earnings Season Begins On Positive Note
DALPositive Net Change AAPositive Net Change PEPPositive Net Change TLRYNegative Net Change
airlines cannabis consumer-discretionary
TLRY Gears Up to Report Q1 Earnings: Cannabis Recovery in Focus
by Zacks Equity Research
Tilray Brands' fiscal first-quarter report is likely to highlight international cannabis gains, European expansion and wellness growth.
EWPositive Net Change INCYNegative Net Change EXASPositive Net Change TLRYNegative Net Change
cannabis earnings medical
2 Agriculture - Products Stocks to Watch Despite Industry Concerns
by Madhurima Das
The near-term outlook for the Zacks Agriculture - Products industry is uncertain. Stocks like ANDE and GRWG are braving the industry headwinds.
ANDEPositive Net Change GRWGNegative Net Change
agriculture basic-materials cannabis
Aurora Cannabis Pre-Q1 Earnings Analysis: Buy, Sell or Hold the Stock?
by Zacks Equity Research
ACB's global medical cannabis momentum stays strong, but near-term regulatory headwinds might have limited Q1 revenue upside.
CGCPositive Net Change TLRYNegative Net Change ACBPositive Net Change
cannabis medical
Do Options Traders Know Something About Aurora Cannabis Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ACB stock based on the movements in the options market lately.
ACBPositive Net Change
cannabis medical medical-devices
GRWG Inks Distribution Agreement With V1 Solutions to Expand Globally
by Zacks Equity Research
GrowGeneration signs V1 Solutions to drive EU distribution and enters Costa Rica, entering deeper into global cannabis markets.
AGIPositive Net Change SSRMPositive Net Change HWKNPositive Net Change GRWGNegative Net Change
basic-materials cannabis
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
by Zacks Equity Research
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
JAZZPositive Net Change PBYIPositive Net Change NTLANegative Net Change
biotechs cannabis earnings marijuana medical pharmaceuticals